BAMATE (meprobamate) by GenexGen is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications. First approved in 1971.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on BAMATE at GenexGen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Cenobamate in Adults With Focal-Onset Seizures
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally